Koyfin Home > Directory > Health Care > Acceleron Pharma > Capital Expenditures

Acceleron Pharma Capital Expenditures Chart (XLRN)

Acceleron Pharma annual/quarterly Capital Expenditures from 2012 to 2020.
  • Acceleron Pharma Capital Expenditures for the quarter ending June 06, 2020 was $-2m a 55.22% decrease of -1m year over year
  • Acceleron Pharma Capital Expenditures for the last 12 months ending June 06, 2020 was $-4m a 35.61% decrease of -2m year over year
  • Acceleron Pharma Annual Capital Expenditures for 2019 was $-3m a 21.20% decrease of -1m from 2018
  • Acceleron Pharma Annual Capital Expenditures for 2018 was $-3m a -69.73% increase of 2m from 2017
  • Acceleron Pharma Annual Capital Expenditures for 2017 was $-4m a 23.11% decrease of -1m from 2016
Other Cash Flow Metrics:
  • Acceleron Pharma Cash Flow from Operations for the quarter ending December 12, 2018 was $-29m a 19.28% decrease of -6m year over year
  • Acceleron Pharma Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-41m a 62.43% decrease of -26m year over year
  • Acceleron Pharma Total Revenue for the quarter ending September 09, 2018 was $3m a -13.72% decrease of 0m year over year
View Chart On Koyfin

Quarterly XLRN Capital Expenditures Data

06/2020$-2m
03/2020$0m
12/2019$-1m
09/2019$-1m
06/2019$-1m
03/2019$-1m
12/2018$-1m
09/2018$-1m
06/2018$-1m
03/2018$-1m

Annual XLRN Capital Expenditures Data

2019$-3m
2018$-3m
2017$-4m
2016$-3m
2015$-1m
2014$-1m
2013$0m
2012$0m
2011$0m